Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB).
Robert Olson, Marjorie Cua, Quinn Matthews...
https://pubmed.ncbi.nlm.nih.gov/40781619/Actively Recruiting
Led by British Columbia Cancer Agency · Updated on 2026-08-26
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are comparing two approaches for Partial Breast Irradiation PBI used after lumpectomy in early-stage breast cancer patients. This study evaluates single fraction SF PBI, where radiation is given in one session, versus multiple fraction MF PBI, where radiation is delivered over several sessions. The aim is to understand how these methods impact quality of life, treatment side effects, and tumor control, especially to reduce travel burdens for patients in remote areas. Participants are randomly assigned to receive PBI either as 26 Gy split into 5 daily doses multiple fraction or as a single 13 Gy dose single fraction. Both treatments target the tumor bed specifically to limit radiation exposure to surrounding tissues like the lungs and heart. This study includes a two-year follow-up to compare outcomes such as local cancer control and toxicity reports. Throughout the study, participants will undergo regular assessments including quality of life questionnaires and toxicity evaluations at baseline and several times up to 24 months post-treatment. Researchers will also monitor local control rates, overall survival, and progression-free survival. The study measures how quickly treatment plans are approved and tracks any adverse events to ensure safety over the two-year period.
CONDITIONS
Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy
R
Robert Olson, MD, MSC, FRCPC
L
Lindsay Mathews
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
British Columbia Cancer Agency
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 week
Participants receive partial breast irradiation either as 5 daily doses or a single dose, targeting the tumor area after lumpectomy.
5 daily visits for multiple fraction group or 1 visit for single fraction group
Duration - 24 months
Participants are monitored regularly for quality of life, side effects, and cancer control through questionnaires and medical exams over two years.
Visits at 6 weeks, 6 months, 12 months, 18 months, and 24 months post-treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Robert Olson, Marjorie Cua, Quinn Matthews...
https://pubmed.ncbi.nlm.nih.gov/40781619/British Columbia Cancer Agency
Lead Sponsor